Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRDT | Q58F21 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24518890 | 0.92 | BRDT (0.31) | BRDT | |
| SCHEMBL24518971 | 0.91 | BRDT (0.30) | BRDT | |
| SCHEMBL24518926 | 0.88 | BRDT (0.33) | BRDTMEN1POLBMAPTDUSP3 | |
| SCHEMBL26492294 | 0.88 | BRDT (0.33) | BRDT | |
| SCHEMBL24518955 | 0.88 | ALOX5 (0.31) | — | |
| SCHEMBL24519000 | 0.85 | BRDT (0.32) | BRDTMEN1POLBMAPTDUSP3 | |
| SCHEMBL24519088 | 0.85 | BRDT (0.40) | BRDTMEN1POLBMAPTDUSP3 | |
| SCHEMBL24519037 | 0.85 | BRDT (0.33) | BRDTMEN1POLBMAPTDUSP3 | |
| SCHEMBL24518898 | 0.84 | ALOX5 (0.33) | MEN1KMT2A | |
| SCHEMBL24518952 | 0.83 | BRDT (0.41) | BRDTMEN1POLBMAPTDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11367838-B2 | Anthracene derivative and organic light-emitting device comprising same | LG CHEM, LTD. (KR) | 2022-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11367838-B2 | Anthracene derivative and organic light-emitting device comprising same | CCNL2, CRY1, CYP2S1 | BRDT 1318/4885MEN1 783/4885POLB 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.